NEW YORK, Dec. 2, 2021 /CNW/ -- Mind Medicine (MindMed)
Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a
leading biotech company developing psychedelic-inspired therapies,
today announced that MindMed's Chief Executive Officer,
Robert Barrow, will provide a
corporate update and the Company's management will participate in
one-on-one investor meetings at the Benzinga Global Small Cap
Conference to be held virtually on December
8-9, 2021.
Details on the conference can be found below.
Format: Corporate update and one-on-one investor meetings
Date: Thursday, December 9, 2021
Time: 4:00 p.m. ET
Webcast: Click Here
The webcast will also be accessible in the "Investors" section
of MindMed's website. MindMed will maintain an archived replay of
the webcast on its website for 30 days after the conference.
About MindMed
MindMed is a clinical-stage psychedelic medicine biotech company
that seeks to discover, develop and deploy psychedelic-inspired
medicines and therapies to address addiction and mental illness.
The Company is assembling a compelling drug development pipeline of
innovative treatments based on psychedelic substances including
psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The
MindMed executive team brings extensive biopharmaceutical
experience to MindMed's approach to developing the next generation
of psychedelic-inspired medicines and therapies.
MindMed trades on the NASDAQ under the symbol MNMD and on the
Canadian NEO Exchange under the
symbol MMED. MindMed is also traded in Germany under the symbol MMQ.
For Media: media@mindmed.co
For Investors: ir@mindmed.co
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mindmed-to-participate-at-the-benzinga-global-small-cap-conference-301436029.html
SOURCE Mind Medicine (MindMed) Inc.